Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Lumbosacral Spondylolysis : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Multimedia
References

Related Articles
Lumbosacral Disc Injuries

Lumbosacral Discogenic Pain Syndrome

Lumbosacral Facet Syndrome

Lumbosacral Spine Acute Bony Injuries

Lumbosacral Spine Sprain/Strain Injuries

Lumbosacral Spondylolisthesis

Lumbosacral Spondylolysis

Myofascial Pain in Athletes

Sacroiliac Joint Injury




Patient Education
Back, Ribs, Neck, and Head Center

Back Pain Overview

Back Pain Causes

Back Pain Symptoms

Back Pain Treatment




Author: Achilles Litao, MD, Staff Physician, Department of Internal Medicine, Lincoln Medical and Mental Health Center, Cornell University

Achilles Litao is a member of the following medical societies: American Academy of Pediatrics, American College of Sports Medicine, and American Medical Association

Coauthor(s): John Munyak, MD, Associate Program Director, Director of Sports Medicine Education, Department of Emergency Medicine, Lincoln Medical and Mental Health Center

Editors: Andrew D Perron, MD, Residency Director, Department of Emergency Medicine, Maine Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Henry T Goitz, MD, Chief, Sports Medicine, Associate Professor, Department of Orthopaedic Surgery, Medical College of Ohio; Jon Whitehurst, MD, Consulting Staff, Rockford Orthopedic Associates; Wylie D Lowery Jr, MD, Associate Professor, Department of Orthopedic Surgery, George Washington University

Author and Editor Disclosure

Synonyms and related keywords: lumbar spondylolysis, pars interarticularis defect, spondylolisthesis, low back pain, lower back pain

Background

Lumbar spondylolysis is a unilateral or bilateral defect of the pars interarticularis affecting one or more of the lumbar vertebrae.

The term is derived from the Greek words spondylos, meaning vertebra, and lysis, meaning break or defect. Numerous hypotheses have been proposed on the etiology of spondylolysis, as follows:

  • Separate ossification centers

  • Fracture during postnatal life

  • Stress fracture (Arriaza, 1997; Morita, 1995)

  • Increased lumbar lordosis

  • Impingement of the articular process on the pars articularis

  • Weakness of supporting structures (Aihara, 2000)

  • Growth (Lonstein, 1999; Morita, 1995)

  • Pathologic changes in the pars articularis

  • Dysplasia of the pars interarticularis

However, mechanical factors are widely believed to be the cause or at least the trigger of the development of spondylolysis, especially when congenital abnormalities are present (Gans, 1998). Moreover, spondylolysis is argued to be related to the human erect posture and lumbar curve (Arriaza, 1997).

Ambulation may have a role in its genesis because no known cases exist in nonambulatory patients (Smith, 1999). As an acquired condition, no reports exist of its occurrence in stillborn fetuses or in the newborn (Dubousset, 1997). Heredity is also implicated (Albanese, 1982).

When the defect in the pars interarticularis is not associated with a forward displacement, the term spondylolysis applies (Stinson, 1993). Spondylolisthesis is from spondylos and listhesis, meaning movement or slipping, and refers to the slipping forward of one vertebra on the next caudal vertebra. Spondylolysis is most common at L5, accounting for 85% of all cases (Patel, 2000), and may be observed as high as L2 (Weiker, 1989). Therefore, a slip is most common at the level of L5 slipping forward on S1. Spondylolysis is the cause of the most common type of spondylolisthesis (Lonstein, 1999). Moreover, a case of spondylolysis that occurred at 3 sites in L5 involving the bilateral pars interarticularis and the center of the right lamina is reported (Ariyoshi, 1999).

Frequency

United States

Spondylolysis is more commonly observed in males (Patel, 2000), but this difference may not be significant (Commandre, 1998; Soler, 2000).

In the United States, a reported difference exists between the sexes and races, with an incidence of spondylolysis of 6.4% in white men, 2.8% in black men, 2.3% in white women, and 1.1% in black women. Pars defect is twice as common in boys than in girls, although high-grade slippage is 4 times more common in girls than in boys. Alaskan Eskimos (26%) have the highest incidence, with the highest rate in Eskimos from north of the Yukon River (Lonstein, 1999).

Functional Anatomy

Repetitive axial loading, especially in an extended lumbar spine is thought to be the most important contributing mechanism, leading to fatigue fracture of the pars interarticularis. Shear stresses on the isthmic pars are greater when the lumbar spine is extended. When repetitive extension stresses occur, the pars interarticularis becomes impinged from the inferior facet of the cephalad vertebrae, which results in microfractures and attempts at repair (Congeni, 1997).

Sport Specific Biomechanics

Spondylolysis occurs in 3-7% of the general population (Soler, 2000). The athletic population is believed to be more prone to the development of spondylolysis (Congeni, 1997) because its incidence in competitive athletes is higher than the percentage reported for the nonsports population (Rossi, 1990). The overall percentage of spondylolysis among athletes in a recent study is about 8%, a figure not significantly higher than that among the general population. However, certain sporting events were found to contribute higher percentages when each sport was considered separately, with the highest percentages occurring in throwing sports (26.67%), artistic gymnastics (16.96%), and rowing (16.88%) (Soler, 2000). In an earlier series, a high percentage of spondylolysis has been observed in diving (43.13%), wrestling (29.82%), and weightlifting (22.68%) (Rossi, 1990).

Other sports with high incidence rates of spondylolysis are ballet, dancing, football, volleyball, and fast bowlers in cricket. In ballet, the higher incidence rate is due in part to an inability to reach or maintain proper turn-out and thus overcompensation with lordosis.

In general, the presence of the repetitive actions of flexion, extension, rotation, and torsion, either alone or in combination, that are often associated with resistance are the biomechanical movements that show the highest prevalence of spondylolysis (Soler, 2000).



History

  • Among the general population, most cases of spondylolysis are clinically inapparent, and spondylolysis is symptomatic in only 10% of patients (Soler, 2000). Many athletes with spondylolysis are likewise asymptomatic (Patel, 2000).
  • Spondylolysis typically occurs in young people (Arriaza, 1997), with a mean age at diagnosis in athletes of about 15-16 years (Patel, 2000).
  • Patients generally report low back pain aggravated by activity (Ralston, 1998), particularly with hyperextension maneuvers such as in gymnastics. In general, patients present without a history of neurologic symptoms (Weiker, 1989).

Physical

  • The physical examination frequently yields minimal findings.
    • No tenderness to palpation is noted, but some discomfort can be elicited with deep percussion over the midline of the lumbar area.

    • Range of motion is full.

    • Because of the previously increased range of motion of dancers and gymnasts, they appear to have normal flexibility. Athletes suspected of having an injury must have their flexibility compared with that of the preinjury state.

    • Forward flexion does not increase symptoms.

    • Hyperextension mimicking the sporting movement generally elicits pain (Weiker, 1989).

    • Sciatica can occur but is rare (Omey, 2000).

    • Physical findings that may also be present include antalgic or normal gait, tight lumbar musculature and hamstrings, hyperlordosis, and buttock or thigh pain.

  • If a unilateral defect is present, the 1-leg hyperextension test elicits pain on the involved side. This test is performed by the patient bearing weight on one leg with both the hip and knee of the other extremity flexed while hyperextending the lumbar spine (Weiker, 1989). The maneuver is performed on both sides, and asymmetric low back pain indicates unilateral disease. Bilateral disease may show symmetric or asymmetric pain with this maneuver (Ralston, 1998).
  • The neurovascular examination findings are normal.
  • The rest of the general low back pain examination must be performed, taking note of all dermatomes, myotomes, and reflexes (Omey, 2000).

Causes

  • The repetitive actions of flexion, extension, rotation, and torsion, either alone or in combination, that are often associated with resistance are the biomechanical movements that show the highest prevalence of spondylolysis (Soler, 2000).
  • In general, athletes may have an increased chance of having symptomatic spondylolysis. Whether the overall incidence is any different than the general population is unknown.



Lumbosacral Disc Injuries
Lumbosacral Discogenic Pain Syndrome
Lumbosacral Facet Syndrome
Lumbosacral Spine Acute Bony Injuries
Lumbosacral Spine Sprain/Strain Injuries
Lumbosacral Spondylolisthesis
Lumbosacral Spondylolysis
Myofascial Pain in Athletes
Sacroiliac Joint Injury

Other Problems to be Considered

Chronic or recurrent low back pain in the adolescent should indicate investigation of an underlying cause because idiopathic low back pain is rare in this age group in contrast to adults. Among the identified causes include the following (Patel, 2000):

Ankylosing spondylitis
Arthritis (eg, rheumatoid arthritis)
Aneurysmal bone cyst
Congenital anomalies
Diskitis
Disk herniation
Leukemia, lymphoma
Lumbar spine inflexibility
Lumbar hypermobility
Lumbosacral sprain
Osteoid osteoma
Osteoblastoma
Osteomyelitis
Osteosarcoma
Postural
Psychosomatic
Scoliosis
Scheuermann disease
Spondylolysis and spondylolisthesis
Spinal process apophysitis (Mannor, 2000)
Spinal stenosis
Schmorl nodes (Sward, 1992)
Trauma
Infections
Inflammations
Neoplasms (cancer)
Developmental abnormalities
Metabolic diseases
Degenerative disorders
Neurologic disorders
Referred pain
Psychological disorders
Miscellaneous



Lab Studies

  • No laboratory studies have been shown to aid in this diagnosis.

Imaging Studies

  • Routine thoracolumbar radiography in an athlete should include anteroposterior (AP), lateral, and oblique views. Flexion and extension lateral radiographs can be added if spondylolisthesis is present or stability is in question.
    • AP radiographic findings are usually normal in spondylolysis (Omey, 2000).

    • The oblique views are particularly screened for the Scotty dog lesion in the pars interarticularis (Weiker, 1989). The pars defect is represented by the collar on the Scotty dog. Keep in mind that the oblique view must be of good quality and read by someone experienced in making the diagnosis. Considerable interobserver variation in making this diagnosis has been noted (Ralston, 1998).

    • The 30° cranially angulated AP view and the coned lateral view of the lumbosacral junction are proposed to display the majority of defects. Because the 30° cranially angulated AP view clearly depicts the pars interarticularis of L5 in the frontal plane, it also allows the distinction between unilateral and bilateral defects (Harvey, 1998). Suffice to say, plain radiography is used more to exclude unusual lesions and spondylolisthesis than to make the diagnosis of spondylolysis (Congeni, 1997).

  • An athlete who is symptomatic with hyperextension and whose plain radiography results are normal requires additional investigations. A 99-m technetium ethylene diphosphonate bone scintigraphy identifies pars interarticularis stress fractures that were missed on oblique plain radiography. Those patients who have had recent trauma or strenuous activity and who are symptomatic show increased activity on the spondylolytic area. On the other hand, those with chronic low back pain show normal scans (Lowe, 1984).
    • The technetium bone scanning has its limitations (Bellah, 1991). When compared to the single-photon emission computed tomography (SPECT) scanning, the latter was found to be more sensitive and better at localization of abnormalities in those athletes with radiographically obvious spondylolysis/spondylolisthesis (Collier, 1985).

    • Bone scanning has a false-positive rate of 15% using CT scanning as the standard to establish the diagnosis of spondylolysis (Congeni, 1997). Therefore, SPECT scanning is needed to identify the more subtle stress reactions. Moreover, these scans can aid in establishing the acuity of the lesion or in identifying the site of the problem in an athlete with negative plain radiography results but whose clinical course is suggestive of a pars interarticularis fracture (Lowe, 1984). The main value of SPECT scanning lies in the identification of an acute stress reaction of the pars prior to its manifestation radiographically (Harvey, 1998).

  • For more information about the defect in the bony structure involved, performing CT scanning through the fracture provides excellent detail. CT scanning also provides information regarding other features of spondylolysis such as facet joint changes, spondylolisthesis, and disc herniations, and it also helps prognosticate the potential for a lesion to heal (Elster, 1985). The technique for CT scanning is crucial because a lesion is optimally demonstrated when the plane of scanning is perpendicular to the plane of fracture. This is achieved if the CT scan gantry is reversed so that the scanning plane is perpendicular to the fracture (Harvey, 1998). CT scanning is not useful for impending stress fractures (Smith, 1999).
  • MRI is inferior to CT scanning for direct visualization of defects of the pars interarticularis (Ulmer, 1997). However, MRI has utility to rule out disc herniations.



Acute Phase

Rehabilitation Program

Physical Therapy

The approach to the treatment of spondylolysis is based on the stage of the bony lesion as guided by radiography and nuclear medicine or SPECT scanning investigations as well as symptomatology (Weiker, 1989; Dutton, 2000). The complete healing of the bony lesion is the ultimate goal in treating patients with spondylolysis.

Acute phase: Some patients present with a spondylolytic defect on plain radiography and also have positive findings on bone scanning. This can represent a recent-onset defect on the pars interarticularis (Weiker, 1989) or a healing spondylolysis. Bracing and rest (Dutton, 2000) are the cornerstones of treatment for this type of lesion. Pain control and avoiding sports are also part of the acute phase or rehabilitation.

Physical therapy: A Boston overlapping brace is used to immobilize the pelvis for prevention of hyperextension and is worn in 0° lordosis for 23 hours per day and for as long as the patient is totally symptom free for a minimum of 3 months, after which a repeat bone scan is performed. Hamstring stretching and lumbar flexibility motions are performed in the brace. Most patients are said to have normal findings on scanning within 3-9 months (Weiker, 1989). Aquatic rehabilitation can also be performed in the acute phase.

Consultations

Consult neurosurgeons, orthopedic surgeons, neurologists, and physiatrists as indicated.

Recovery Phase

Rehabilitation Program

Physical Therapy

Recovery phase: The goals of this phase are the resolution of pain and the healing of the pars defect with either bony union or painless fibrous union if bony union is not possible.

Physical therapy: This phase of rehabilitation consists of a progressively shallower aquatic rehabilitation location so that graded gravitational forces are applied to the spine. Also, lumbar flexibility out of the brace as symptoms resolve is helpful, but inciting activities must still be avoided. Flexibility and strengthening of the paraspinal, iliopsoas, and abdominal muscles along with endurance training of the back (necessitated by deconditioning) are all especially important. One may advance to full participation in a brace as symptoms resolve.

Consultations

Consult neurosurgeons, orthopedic surgeons, neurologists, and physiatrists as indicated.

Other Treatment (Injection, manipulation, etc.)

Electromagnetic field therapy for persistent nonunion may be used in this phase.

Maintenance Phase

Rehabilitation Program

Physical Therapy

Maintenance phase: The single best predictor for a new injury during athletic activity is a history of a previous injury. Patients showing a spondylolytic defect on plain radiography but whose bone scanning result is negative are regarded as having an inactive spondylolytic defect (Weiker, 1989) or a pseudoarthrosis or old unhealed fracture (Dutton, 2000).

Physical therapy: Continue bracing for up to 6-9 months is indicated as necessary to heal the pars. These patients benefit from physical therapy that puts emphasis in deep abdominal muscles, specifically the internal oblique and transversus abdominis and the lumbar multifidus (O'Sullivan, 1997), in addition to flexibility exercises for the hamstrings and lower back. Hyperextension movements are avoided. One may need SPECT bone scanning or CT scanning to monitor healing.

Surgical Intervention

Some advocate surgery to prevent spondylolisthesis (Dutton, 2000).

Consultations

Consult neurosurgeons, orthopedic surgeons, neurologists, and physiatrists as indicated.

Other Treatment

Lumbar corsets and neoprene belts are also used (Weiker, 1989).



Tylenol (acetaminophen) and NSAIDs are the mainstays of pain control. Moreover, a short course of narcotic analgesics can help those who are in significant acute pain initially.

Muscle relaxants are overprescribed and have not been demonstrated to be of significant help.

Drug Category: Analgesics

Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who experience pain.

For the relief of moderate to severe pain, a short course of narcotic analgesic may be warranted. Opiates exert their effects by binding to different opioid receptors throughout the body, which produces a wide range of effects such as analgesia, euphoria, constipation, and respiratory depression.

Drug NameAcetaminophen (Tylenol, Feverall, Aspirin-Free Anacin)
DescriptionEffective analgesic-antipyretic but only has weak anti-inflammatory effects. Inhibits prostaglandin synthetase. Well absorbed from gastrointestinal tract. Peak concentrations in serum are reached within 2 h.
Adult Dose500-1000 mg q4h PO prn for pain
Pediatric Dose10-15 mg/kg q4h PO prn for pain; not to exceed adult dose
ContraindicationsDocumented hypersensitivity; known G-6-PD deficiency
InteractionsRifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsHepatotoxicity is possible in people with long-term alcoholism following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; APAP is contained in many OTC products, and combined use with these products may result in cumulative APAP doses exceeding recommended maximum dose

Drug NameAcetaminophen and codeine (Tylenol #3)
DescriptionIndicated for the treatment of mild to moderate pain.
Adult Dose30-60 mg/dose PO based on codeine content q4-6h or 1-2 tab q4h; not to exceed 4 g/d of acetaminophen
Pediatric Dose0.5-1 mg/kg/dose PO based on codeine q4-6h; 10-15 mg/kg/dose based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen
ContraindicationsDocumented hypersensitivity
InteractionsToxicity of codeine increases with CNS depressants, tricyclic antidepressants, MAOIs, neuromuscular blockers, CNS depressants, phenothiazines, and narcotic analgesics
Rifampin can reduce analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity of acetaminophen
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in patients dependent on opiates because this substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction
Hepatotoxicity with acetaminophen possible in people with long-term alcoholism following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; acetaminophen is contained in many OTC products, and combined use with these products may result in cumulative acetaminophen doses exceeding recommended maximum dose

Drug NameHydrocodone and acetaminophen (Lortab, Lorcet-HD, Vicodin, Norcet)
DescriptionDrug combination indicated for moderate to severe pain. Available in different strengths.
Adult Dose1-2 tab PO q4-6h; not to exceed 4 g/d of acetaminophen
Pediatric Dose<12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d acetaminophen
>12 years: 750 mg acetaminophen PO q4h; not to exceed 10 mg hydrocodone bitartrate per dose or 5 doses/24 h
ContraindicationsDocumented hypersensitivity to hydrocodone, acetaminophen or components; high altitude cerebral edema (HACE) or elevated intracranial pressure (ICP)
InteractionsCoadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or tricyclic antidepressants
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsTabs contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates because this substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction; tolerance or drug dependence may result from prolonged use

Drug NameHydrocodone and ibuprofen (Vicoprofen)
DescriptionDrug combination indicated for short-term (<10 d) relief of moderate to severe acute pain.
Adult Dose1-2 tab PO q4-6h prn pain; not to exceed 5 tab/d
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; third trimester of pregnancy
InteractionsCoadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in impaired renal function, peptic ulcer disease, impaired thyroid function, asthma, hypertension, edema, heart failure, increased intracranial pressure, and erosive gastritis; duration of action may increase in elderly patients

Drug NamePropoxyphene and acetaminophen (Darvocet-N100, Wygesic)
DescriptionDrug combination indicated for mild to moderate pain.
Adult Dose1-2 tab PO q4h prn; not to exceed 600 mg/d
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity
InteractionsMay increase serum concentrations of MAOIs, tricyclic antidepressants, carbamazepine, phenobarbital, and warfarin
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in patients dependent on opiates because substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction

Drug Category: Nonsteroidal anti-inflammatory drugs (NSAIDs)

Have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclooxygenase (COX) activity and prostaglandin synthesis. Other mechanisms may exist as well, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions.

Drug NameNaproxen (Anaprox, Naprelan, Naprosyn, Aleve)
DescriptionFor relief of mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing activity of COX, which results in a decrease of prostaglandin synthesis.
Adult Dose500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d
Pediatric Dose<2 years: Not established
>2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d
ContraindicationsDocumented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency
InteractionsCoadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsCategory D in third trimester of pregnancy; acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug

Drug NameIbuprofen (Motrin, Ibuprin, Advil)
DescriptionNSAIDS exert their main therapeutic effect on pain and inflammation principally by inhibition of prostaglandin synthesis.
Adult Dose400 mg q4-6h prn mild to moderate pain
Pediatric Dose10 mg/kg q6h
ContraindicationsDocumented hypersensitivity
InteractionsMay decrease anti-hypertensive effect of angiotensin-converting enzyme (ACE) inhibitors; can reduce the natriuretic effect of furosemide and thiazides in some patients; reduces lithium clearance
PregnancyB - Usually safe but benefits must outweigh the risks
PrecautionsUse of NSAIDS is not recommended during pregnancy, labor, and delivery and in nursing mothers; use of NSAIDS may result in or aggravate gastrointestinal adverse effects and bleeding and cause hypersensitivity reactions

Drug NameMefenamic acid (Ponstel)
DescriptionInhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.
Adult Dose500 mg PO initially then 250 mg q6h prn for not more than 1 wk
Pediatric Dose<14 years: Not established
>14 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding
InteractionsCoadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCategory D in third trimester of pregnancy; may have adverse effects in fetus; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy

Drug NameKetoprofen (Orudis, Oruvail, Actron)
DescriptionFor relief of mild to moderate pain and inflammation.
Small dosages are initially indicated in small and elderly patients and in those with renal or liver disease.
Doses >75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response.
Adult Dose25-50 mg PO q6-8h prn; not to exceed 300 mg/d
Pediatric Dose3 months to 12 years: 0.1-1 mg/kg PO q6-8h
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsCategory D in third trimester of pregnancy; caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy

Drug NameRofecoxib (Vioxx)
DescriptionOn September 30, 2004, Merck & Co, Inc, announced a voluntary withdrawal of rofecoxib (Vioxx) from the US and worldwide market because of its association with an increased rate of cardiovascular events (including heart attacks and strokes) compared to that of placebo.
Inhibits primarily COX-2. COX-2 is considered an inducible isoenzyme induced during pain and inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID GI toxicity. At therapeutic concentrations, COX-1 isoenzyme is not inhibited, thus GI toxicity may be decreased. Seek lowest dose of rofecoxib for each patient.The susp dose, 12.5 mg/5 mL or 25 mg/5 mL, may be substituted for 12.5- or 25-mg tabs, respectively.
Adult Dose50 mg PO qd; subsequent doses are 50 mg qd prn; use for >5 d in management of pain not established; tabs may be taken with or without food
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with fluconazole may cause increase in rofecoxib plasma concentrations because of inhibition of rofecoxib metabolism; coadministration of rofecoxib with rifampin may decrease rofecoxib plasma concentrations
PregnancyB - Usually safe but benefits must outweigh the risks
PrecautionsMay cause fluid retention and peripheral edema; caution in compromised cardiac function, hypertension, and conditions predisposing to fluid retention; caution in severe heart failure and hyponatremia because may deteriorate circulatory hemodynamics; NSAIDs may mask usual signs of infection; caution in the presence of existing controlled infections; evaluate therapy when symptoms or laboratory results suggest liver dysfunction
Alert: On September 30, 2004, Merck & Co, Inc, announced a voluntary withdrawal of rofecoxib (Vioxx) from the US and worldwide market because of its association with an increased rate of cardiovascular events (including heart attacks and strokes) compared to that of placebo. A major FDA study of rofecoxib found an apparent 3-fold increase in the risk of sudden cardiac death or heart attack among patients who had taken higher doses of the drug compared to the risk of patients who had not recently received similar medication. The report showed that even patients taking the standard starting dose of 12.5 mg or 25 mg of rofecoxib had a 50% greater chance of heart attack or sudden cardiac death than patients on any dose of celecoxib (Celebrex). The large-scale study was conducted after analyzing the medical records of 1.4 million people insured by Kaiser Permanente in Oakland, Calif, between 1999-2001. Note: The study has inherent limitations in that it is observational, rather than randomized and controlled.

Drug NameValdecoxib (Bextra)
DescriptionAlert: On April 7, 2005, valdecoxib (Bextra, by Pfizer, Inc) was voluntarily withdrawn from the US market, pending further discussion with the US Food and Drug Administration (FDA). The association of valdecoxib with potentially life-threatening risks, including myocardial infarction, stroke, and serious skin reactions, initiated an investigation to determine whether the benefits of the drug outweighed the risks.
Second-generation COX-2 inhibitor that offers a very rapid onset and prolonged efficacy. Inhibits primarily COX-2. COX-2 is considered an inducible isoenzyme induced during pain and inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID GI toxicity. At therapeutic concentrations, valdecoxib does not inhibit COX-1 isoenzyme, decreasing GI toxicity.
Adult Dose10 mg PO qd
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with fluconazole may increase valdecoxib plasma concentrations; coadministration with rifampin may decrease valdecoxib plasma concentrations
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCategory D in third trimester of pregnancy; abdominal pain, nausea, and diarrhea may occur; caution in compromised cardiac function, hypertension, and conditions predisposing to fluid retention; caution in severe heart failure and hyponatremia because may deteriorate circulatory hemodynamics; NSAIDs may mask usual signs of infection; caution in the presence of existing controlled infections; evaluate therapy when symptoms or laboratory results suggest liver dysfunction
Alert: On April 7, 2005, valdecoxib (Bextra, by Pfizer, Inc) was voluntarily withdrawn from the US market, pending further discussion with the US Food and Drug Administration (FDA). The association of valdecoxib with potentially life-threatening risks, including myocardial infarction, stroke, and serious skin reactions, initiated an investigation to determine whether the benefits of the drug outweighed the risks. In 2004, the FDA had Pfizer add a boxed, bolded warning to the prescribing information to alert health care professionals and patients about the serious adverse effects.
Serious, potentially fatal skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, may occur. These reactions are most likely to happen in the first 2 weeks of treatment, but they can occur any time during therapy. Valdecoxib should be discontinued at the first sign of rash, mouth sores, and/or allergic reaction (eg, swelling, itching, shortness of breath). Other COX-2 inhibitors (eg, rofecoxib [Vioxx], celecoxib [Celebrex]) and traditional NSAIDs (eg, naproxen [Aleve, Naprosyn], ibuprofen [Motrin]) also have a risk for these rare, serious skin reactions, but the reported rate of the reactions appears to be greater for valdecoxib.
New data regarding cardiovascular risks are also highlighted, including data from more than 1500 patients treated after CABG. The patients treated with valdecoxib showed an increased cardiovascular risk compared to those treated with placebos. Observed cardiovascular events included myocardial infarction, cerebrovascular accident, deep vein thrombosis, and pulmonary embolism.
Pfizer submitted the final report of the new CABG study to the FDA on November 5, 2004. The report confirms the risk of the intravenous form (~2% of patients experienced adverse cardiovascular events) and also shows that oral valdecoxib is associated with a lower risk (~1% of patients) immediately following CABG surgery. In the placebo group, about 0.5% of patients had an adverse cardiovascular event.

Drug NameCelecoxib (Celebrex)
DescriptionInhibits primarily COX-2. COX-2 is considered an inducible isoenzyme induced during pain and inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID GI toxicity. At therapeutic concentrations, COX-1 isoenzyme is not inhibited, thus GI toxicity may be decreased. Seek lowest dose of celecoxib for each patient.
Adult Dose200 mg/d PO qd; alternatively, 100 mg PO bid
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with fluconazole may increase celecoxib plasma concentrations because of inhibition of celecoxib metabolism; coadministration with rifampin may decrease celecoxib plasma concentrations
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsCategory D in third trimester of pregnancy; may cause fluid retention and peripheral edema; caution in compromised cardiac function, hypertension, and conditions predisposing to fluid retention; caution in severe heart failure and hyponatremia because may deteriorate circulatory hemodynamics; NSAIDs may mask usual signs of infection; caution in the presence of existing controlled infections; evaluate therapy when symptoms or laboratory results suggest liver dysfunction

Drug Category: Muscle relaxants

Muscle relaxants are overprescribed and have not been demonstrated to be of significant help.

Drug NameMethocarbamol/aspirin
DescriptionUsed mainly as adjunctive treatment of muscle spasm associated with acute painful musculoskeletal conditions. It causes musculoskeletal relaxation by decreasing impulse transmission from the spinal cord to the muscle.
Adult Dose2 tabs qid
Pediatric Dose>12 years: 2 tabs qid
ContraindicationsDocumented hypersensitivity
InteractionsIncreased toxicity with CNS depressants; aspirin blunts antihypertensive effect of ACE inhibitors
PregnancyC - Safety for use during pregnancy has not been established
PrecautionsAvoid in patients with underlying bleeding and platelet disorders (increases risk of bleeding), peptic ulcer disease, and renal dysfunction



Return to Play

Return to play is first begun with low-level sport activities after the follow-up visit at 4-6 weeks, after which gradual increase in intensity as tolerated is allowed under supervision (Moeller, 2001). Return to full activity is permitted only when patients are totally asymptomatic with full range of motion (Weiker, 1989). Patients must also have normal flexibility and normal strength and balance.

Complications

Complications include a progression to spondylolisthesis (ie, slippage of the vertebrae and its sequelae) as well as delayed diagnosis and nonunion with chronic pain.

Prevention

Because the etiology is unknown and factors that cause slippage are unknown, prevention suggestions are unavailable. However, athletes must be advised that preventing recurrences may prove difficult if they return to high-level competition.

Prognosis

If treatment is instituted early, lumbar spondylolysis can be successfully treated with conservative management (Morita, 1995). The cure rate for early spondylolysis with activity restriction and a thoracolumbosacral orthosis is 73%, while more advanced spondylolyses were found to be less responsive to this regimen (Morita, 1995).

With history and physical examination findings compatible with spondylolysis, athletes with normal findings on plain radiography and bone scanning are most likely to have pathology other than a pars defect. They are presumed to have a chronic back strain, and further investigation of the cause of the back pain is indicated while they are placed on physical therapy. Studies are repeated in 6-8 weeks if patients are still symptomatic with physical therapy (Weiker, 1989). MRI is appropriate in this setting (Dutton, 2000).

Surgical treatment is an option for persistently symptomatic patients who did not achieve bony healing with activity restriction and bracing (Buck, 1970; Morscher, 1984; Scott, 1987; Kakiuchi, 1997; Wu, 1999; Chen, 2000; De Gauzy, 2000). Bony union has also been reported with transcutaneous electrical stimulation in this group of patients (Fellander-Tsai, 1998).

Education

All athletes, especially those younger than 18 years, should know that not all sources of back pain are muscular and, therefore, should not be ignored if persistent. This is most important if the athlete is participating in gymnastics, football, dancing, or figure skating.

For excellent patient education resources, visit eMedicine's Back, Ribs, Neck, and Head Center. Also, see eMedicine's patient education article Back Pain.



Medical/Legal Pitfalls

  • Misdiagnosis as benign back pain and progression to spondylolisthesis

Special Concerns

  • Adults may have degenerative discs, facet arthrosis, or spinal stenosis along with spondylolysis, thus confounding treatment.
  • An athlete younger than 18 years with low back pain has a 45% likelihood of having spondylolysis (Micheli, 1995).



Media file 1:  Lumbosacral spondylolysis. Radiograph of L4 defect in the pars interarticularis.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  X-RAY

Media file 2:  Lumbosacral spondylolysis. CT scan demonstrating defects in the left and right pars interarticularis.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  CT



  • Aihara T, Takahashi K, Yamagata M, et al. Biomechanical functions of the iliolumbar ligament in L5 spondylolysis. J Orthop Sci. 2000;5(3):238-42. [Medline].
  • Albanese M, Pizzutillo PD. Family study of spondylolysis and spondylolisthesis. J Pediatr Orthop. 1982;2(5):496-9. [Medline].
  • Ariyoshi M, Nagata K, Sonoda K, et al. Spondylolysis at three sites in the same lumbar vertebra. Int J Sports Med. Jan 1999;20(1):56-7. [Medline].
  • Arriaza BT. Spondylolysis in prehistoric human remains from Guam and its possible etiology. Am J Phys Anthropol. Nov 1997;104(3):393-7. [Medline].
  • Bellah RD, Summerville DA, Treves ST, Micheli LJ. Low-back pain in adolescent athletes: detection of stress injury to the pars interarticularis with SPECT. Radiology. Aug 1991;180(2):509-12. [Medline].
  • Buck JE. Direct repair of the defect in spondylolisthesis. Preliminary report. J Bone Joint Surg Br. Aug 1970;52(3):432-7. [Medline].
  • Chen JF, Lee ST. A physiological method for the repair of young adult simple isthmic lumbar spondylolysis. Chang Gung Med J. Feb 2000;23(2):92-8. [Medline].
  • Collier BD, Johnson RP, Carrera GF, et al. Painful spondylolysis or spondylolisthesis studied by radiography and single-photon emission computed tomography. Radiology. Jan 1985;154(1):207-11. [Medline].
  • Commandre FA, Taillan B, Gagnerie F, et al. Spondylolysis and spondylolisthesis in young athletes: 28 cases. J Sports Med Phys Fitness. Mar 1988;28(1):104-7. [Medline].
  • Congeni J, McCulloch J, Swanson K. Lumbar spondylolysis. A study of natural progression in athletes. Am J Sports Med. Mar-Apr 1997;25(2):248-53. [Medline].
  • Dubousset J. Treatment of spondylolysis and spondylolisthesis in children and adolescents. Clin Orthop. Apr 1997;(337):77-85. [Medline].
  • Dutton JA, Hughes SP, Peters AM. SPECT in the management of patients with back pain and spondylolysis. Clin Nucl Med. Feb 2000;25(2):93-6. [Medline].
  • Elster AD, Jensen KM. Computed tomography of spondylolisthesis: patterns of associated pathology. J Comput Assist Tomogr. Sep-Oct 1985;9(5):867-74. [Medline].
  • Fellander-Tsai L, Micheli LJ. Treatment of spondylolysis with external electrical stimulation and bracing in adolescent athletes: a report of two cases. Clin J Sport Med. Jul 1998;8(3):232-4. [Medline].
  • Gans BM, ed. Rehabilitation Medicine: Principles and Practice. 3rd ed. Philadelphia, Pa: Lippincott-Raven; 1998:1646.
  • Harvey CJ, Richenberg JL, Saifuddin A, Wolman RL. The radiological investigation of lumbar spondylolysis. Clin Radiol. Oct 1998;53(10):723-8. [Medline].
  • Kakiuchi M. Repair of the defect in spondylolysis. Durable fixation with pedicle screws and laminar hooks. J Bone Joint Surg Am. Jun 1997;79(6):818-25. [Medline].
  • Lonstein JE. Spondylolisthesis in children. Cause, natural history, and management. Spine. Dec 15 1999;24(24):2640-8. [Medline].
  • Lowe J, Schachner E, Hirschberg E, et al. Significance of bone scintigraphy in symptomatic spondylolysis. Spine. Sep 1984;9(6):653-5. [Medline].
  • Mannor DA, Lindenfeld TN. Spinal process apophysitis mimics spondylolysis. Case reports. Am J Sports Med. Mar-Apr 2000;28(2):257-60. [Medline].
  • Medical Economics, ed. Physicians' Desk Reference. 54th ed. Montvale, NJ: Thomson; 2000.
  • Micheli LJ, Wood R. Back pain in young athletes. Significant differences from adults in causes and patterns. Arch Pediatr Adolesc Med. Jan 1995;149(1):15-8. [Medline].
  • Moeller JL, Rifat SF. Spondylolysis in Active Adolescents. The Physician and Sportsmedicine. Dec 2001;29(12):27-32.
  • Morita T, Ikata T, Katoh S, Miyake R. Lumbar spondylolysis in children and adolescents. J Bone Joint Surg Br. Jul 1995;77(4):620-5. [Medline].
  • Morscher E, Gerber B, Fasel J. Surgical treatment of spondylolisthesis by bone grafting and direct stabilization of spondylolysis by means of a hook screw. Arch Orthop Trauma Surg. 1984;103(3):175-8. [Medline].
  • O'Sullivan PB, Phyty GD, Twomey LT, Allison GT. Evaluation of specific stabilizing exercise in the treatment of chronic low back pain with radiologic diagnosis of spondylolysis or spondylolisthesis. Spine. Dec 15 1997;22(24):2959-67. [Medline].
  • Omey ML, Micheli LJ, Gerbino PG 2nd. Idiopathic scoliosis and spondylolysis in the female athlete. Tips for treatment. Clin Orthop Relat Res. Mar 2000;(372):74-84. [Medline].
  • Patel DR, Nelson TL. Sports injuries in adolescents. Med Clin North Am. Jul 2000;84(4):983-1007, viii. [Medline].
  • Ralston S, Weir M. Suspecting lumbar spondylolysis in adolescent low back pain. Clin Pediatr (Phila). May 1998;37(5):287-93. [Medline].
  • Rossi F, Dragoni S. Lumbar spondylolysis: occurrence in competitive athletes. Updated achievements in a series of 390 cases. J Sports Med Phys Fitness. Dec 1990;30(4):450-2. [Medline].
  • Sales de Gauzy J, Vadier F, Cahuzac JP. Repair of lumbar spondylolysis using Morscher material: 14 children followed for 1-5 years. Acta Orthop Scand. Jun 2000;71(3):292-6. [Medline].
  • Scott JH. The Edinburgh Repair of Isthmic (Group II) Spondylolysis. J Bone Joint Surg Br. 1987;69:491.
  • Smith JA, Hu SS. Management of spondylolysis and spondylolisthesis in the pediatric and adolescent population. Orthop Clin North Am. Jul 1999;30(3):487-99, ix. [Medline].
  • Soler T, Calderón C. The prevalence of spondylolysis in the Spanish elite athlete. Am J Sports Med. Jan-Feb 2000;28(1):57-62. [Medline].
  • Stinson JT. Spondylolysis and spondylolisthesis in the athlete. Clin Sports Med. Jul 1993;12(3):517-28. [Medline].
  • Swärd L. The thoracolumbar spine in young elite athletes. Current concepts on the effects of physical training. Sports Med. May 1992;13(5):357-64. [Medline].
  • Ulmer JL, Mathews VP, Elster AD, et al. MR imaging of lumbar spondylolysis: the importance of ancillary observations. AJR Am J Roentgenol. Jul 1997;169(1):233-9. [Medline].
  • Weiker GG. Evaluation and treatment of common spine and trunk problems. Clin Sports Med. Jul 1989;8(3):399-417. [Medline].
  • Wu SS, Lee CH, Chen PQ. Operative repair of symptomatic spondylolysis following a positive response to diagnostic pars injection. J Spinal Disord. Feb 1999;12(1):10-6. [Medline].

Lumbosacral Spondylolysis excerpt

Article Last Updated: Jul 22, 2005